Decibel Appoints Jeff Jonas To Board
This article was originally published in Scrip
Decibel Therapeutics has appointed SAGE Therapeutics' CEO, Jeff Jonas, to its board of directors. Jonas has been CEO of SAGE since 2013 and prior to this he was at Shire Plc., where he was most recently president of the regenerative medicine division and before that senior vice-president of R&D pharmaceuticals. Before Shire, Jonas held senior-level positions at ISIS Pharmaceuticals, Forest Laboratories Inc. and Upjohn Laboratories. He also founded AVAX Technologies and SCEPTOR Industries and served on the board for Cara Therapeutics, Inc. and AVAX Technologies.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.